Arindam Dhar

Arindam Dhar is the Executive Director of Clinical Development - Immuno-Oncology at GSK, where they lead the clinical development of multiple immuno-oncology assets and oversee Phase 1 to Phase 3 clinical trials. They previously held roles at the National Cancer Institute, the Food and Drug Administration, and Bristol-Myers Squibb, focusing on oncology therapeutics and clinical research. Arindam completed their PhD in Molecular Biology and Biotechnology at the All India Institute of Medical Sciences and holds an MD from the same institution. Additionally, they have an Executive Certificate in Artificial Intelligence from MIT Sloan.